Ghulam Rehman Mohyuddin
University of Kansas
H-index: 12
North America-United States
Top articles of Ghulam Rehman Mohyuddin
Overtreatment of multiple myeloma and its precursor states: de-escalation is an urgent need in clinical practice and trials
2024/4/22
Ghulam Rehman Mohyuddin
H-Index: 5
Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study
Blood
2023/11/28
Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma
Blood
2023/11/28
Ghulam Rehman Mohyuddin
H-Index: 5
Dietary interventions in cancer: a systematic review of all randomized controlled trials
2024/3/1
Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study
Clinical Lymphoma Myeloma and Leukemia
2024/2/14
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review
2024/1/25
Meera Mohan
H-Index: 6
Ghulam Rehman Mohyuddin
H-Index: 5
Ineligible for transplant, but eligible for intensive quadruplet therapy—The value of ‘add-on’trials for vulnerable patient populations
European Journal of Cancer
2023/5/1
Ghulam Rehman Mohyuddin
H-Index: 5
Relapsed and Refractory Multiple Myeloma with Pleural Involvement: A Case Series
Blood
2023/11/28
Douglas Peters
H-Index: 1
Ghulam Rehman Mohyuddin
H-Index: 5
Acknowledging infection risk in bispecific antibody trials in the treatment of multiple myeloma
Journal of Clinical Oncology
2023/4/1
Gemma Reynolds
H-Index: 10
Ghulam Rehman Mohyuddin
H-Index: 5
Time‐to‐event surrogate end‐points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis
2023/3
Vinay Prasad
H-Index: 18
Alyson Haslam
H-Index: 10
Samer Al Hadidi
H-Index: 5
Aaron Goodman
H-Index: 8
Ghulam Rehman Mohyuddin
H-Index: 5
Performance of Newer Staging Systems for Myeloma in a Contemporary, Large Cohort of Patients in the United States
Blood
2023/11/28
Ghulam Rehman Mohyuddin
H-Index: 5
Xiaoyan Wang
H-Index: 3
The promise and harms of screening for plasma cell dyscrasias
2023/3
Ghulam Rehman Mohyuddin
H-Index: 5
Analysis of repeated roles in editorial boards at oncology focused journals
Journal of Cancer Policy
2023/3/1
Ghulam Rehman Mohyuddin
H-Index: 5
Samer Al Hadidi
H-Index: 5
Prevalence of Exclusion Criteria in Multiple Myeloma Randomized Controlled Trials: A Systematic Review
2023/11/28
A window of opportunity trial evaluating intratumoral injection of Copaxone® in patients with percutaneously accessible tumors
Translational Medicine Communications
2023/2/27
Ghulam Rehman Mohyuddin
H-Index: 5
Carfilzomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (KDCEP) for the Treatment of Relapsed/Refractory Aggressive Plasma Cell Dyscrasias
Blood
2023/11/28
Ghulam Rehman Mohyuddin
H-Index: 5
Christmas 2023: Marginal Gains: Projecting complete redaction of clinical trial protocols (RAPTURE): redacted cross sectional study
The BMJ
2023
Ghulam Rehman Mohyuddin
H-Index: 5
Gal Markel
H-Index: 29
David Bomze
H-Index: 13
Tomer Meirson
H-Index: 11
Adverse event reporting in randomized clinical trials for multiple myeloma
JAMA Network Open
2023/11/1
Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity
2023
Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey
Eclinicalmedicine
2023/11/1
Ghulam Rehman Mohyuddin
H-Index: 5
Benjamin A Derman
H-Index: 7
